posted
Herborium Group, Inc., is a novel botanical therapeutics® company focused on developing, licensing, and marketing of proprietary, botanical based medicinal products, targeting unmet medical needs. The Company responds to both consumers and healthcare professionals demand for safe, efficacious, all natural medicinal options for treatment and prevention of selected diseases and health concerns.
Posts: 428 | From: Michigan | Registered: Oct 2009
| IP: Logged |
posted
HBRM after hour News: Herborium Group, Inc. Focuses on a Lucrative Botanical Therapeutics Market
SADDLE BROOK, NJ -- (Marketwire) 05/28/10 Herborium Group, Inc. (PINKSHEETS: HBRM) (www.herborium.com), a botanical therapeutics® company that develops, licenses and markets all natural, herbal medicinal products, has focused its efforts on developing aggressive routes of taping into $33 billion over the counter alternative medicine market in the USA and over a trillion USD global market for alternative and complementary medicine.
The Company business model focuses on emerging market opportunities spearheaded by the growth of a new market sector located between high-cost, high-risk, ethical pharmaceuticals and commoditized classic nutraceuticals (supplements). The Company uses clinical validation and a proactive regulatory strategy based on the FDA Guidance for Industry: Botanical Drug Products (FDA Guidance 2004) to establish and maintain a differential advantage.
Herborium pipeline of botanical therapeutics in the sectors of dermatology (Acne -- global market is over 55 Billion USD and over 60 million Americans are diagnosed and affected yearly by different forms of acne -- www.acnease.com), women's and men's health, including BPH (benign prostate hyperplasia affects over half of male population at the age of 50+) and liver health, belong to the most growing category of CAM products (self care costs) that reached $22 Billion in the US last year with majority going to purchase of non-vitamin, and non-mineral products.
"With the conversion of such factors as health economics, directing consumers to spend money on prevention and on non ethical products (lower insurance coverage) and to pharmaceutical companies being forced to remove drugs from the market for safety reasons (La Roche and Accutane for acne or Vioxx for pain), Herborium is ideally positioned to take advantage of those emerging market opportunities," said Dr. Agnes P. Olszewski, President of Herborium Group. "During last four months we have focused our activities on preparing to penetrate new markets with our existing products including targeting of foreign markets. We have signed or are in final stage of negotiating new distribution agreements in the USA and abroad that will greatly increase our customer base. We expect that our bottom line will significantly benefit from those initiatives in 2010 and 2011," continues Dr. Olszewski.
"We are also planning to introduce new and complementary products. We are especially excited about expected product line extension in the field of dermatology with a product targeting acne," adds Dr. Olszewski
"While securing additional resources we plan to address needs of consumers and health providers that look for highly efficient, proven safe and effective all natural alternatives in treatment and prevention of number of health problems and concerns," concludes Dr. Olszewski
Posts: 428 | From: Michigan | Registered: Oct 2009
| IP: Logged |
from microcap website they have 8 million shares to dump::::
http://www.microcapreports.com has not been compensated for this report however is an accredited investor and has purchased 10 million shares of AMSZ and 8 million shares of HBRM from a 3rd party debt holder from a non-controlling, non-affiliated 3rd party. We intend to sell our shares into market which could negatively affect the stock price. Investing in penny stocks is very risky and we invite anyone to please review the information provided by the SEC pertaining to penny stock rules http://www.sec.gov/
-------------------- Buy Low. Sell High. Posts: 10750 | From: The Land Of The Giants | Registered: Feb 2005
| IP: Logged |
posted
HBRM - Do their products work? After doing some research, they do work. AcnEase is their flagship product so we are bringing you reviews of it this morning. Read on and make up your own mind to the efficacy of the product.
The company is stepping into the acne arena armed with a product that effectively treats the diseased area without the use of a topical treatment. No creams or ointments to apply multiple times daily.
The market for OTC acne treatments alone was projected to pass the 550 million dollar mark by the year 2008. This dollar amount reperesents nearly 17% of the OTC medicated skin care market.
As a population, the USA has the largest percentage of overweight teens and young adults, those most likely to contract acne through poor diet alone.
As you can see, the market demand for AcnEase, coupled with the fact it really works, makes for an easy entry for Herborium Group to step onto the center stage as a leading provider for over the counter skin care treatment.
The science behind AcnEase. AcnEase is a proprietary herbal acne treatment that was developed based on principles of Traditional Chinese Medicine and modern herbaceutical and pharmacological science. This all natural product is formulated with a Patented and Trade Secret protected blend of the highest quality herbal extracts.
The ability of AcnEase to serve as a natural acne treatment and to provide a natural acne cure is assured by extensive testing and strictly controlled manufacturing conditions. The ratio of the ingredients, the selection of herbs and the method of extraction are key factors in assuring the efficacy of AcnEase as a premium natural acne treatment.
Benefits: This unique acne treatment works in several ways: AcnEase prevents the forming of new pimples, whiteheads and blackheads and significantly improves symptoms associated with Adult Acne, Cystic Acne, Teen Acne and Body Acne.
AcnEase also reduces facial flushing and the incidence of blepheritis (itchy gritty eyes) and gastric reflux (heartburn), symptoms often associated with Rosacea.
posted
Herborium Group Names Dr. Harold Mermelshein MD to Its Scientific Advisory Board
Marketwire "Press Releases " SADDLE BROOK, NJ -- (MARKET WIRE) -- 06/15/10 -- Herborium Group, Inc. (PINKSHEETS: HBRM), a Botanical Therapeutics™ company, today announced the appointment of Dr. Harold Mermelshein, MD, a renowned New York dermatologist, to Herborium'sScientific Advisory Board.
"I'm pleased that such a prestigious dermatologist as Dr. Mermelshein has agreed to serve on our Scientific Advisory Board," commented Dr. Agnes P. Olszewski, Herborium Group's president and chief executive officer. "Dr. Mermelshein's career spans more than 30 years, during which time he has distinguished himself as a dedicated, learned advocate in dermatological academia, research, and clinical practice as well as pioneer in using complementary, scientifically based, alternative treatment modalities in clinical practice."
Dr. Mermelshein is Board Certified by, and a standing member of, the American Academy of Dermatology. A magna cum laude alumnus of New York Medical College. Dr. Mermelshein has served as Chief of Residency for New York University Medical Center's Skin and Cancer Unit and, since 1988, as the Associate Clinical Professor of the Center Dermatology Department.
Dr. Olszewski continued, "With Herborium's flagship product, AcnEase®, now available through an increasing number of distribution channels in the US and abroad, we are focusing on strengthening its consumer and professional brand recognition. Dr. Mermelshein will play a key role in meeting and maintaining only the highest standards expected by medical professionals and consumers, further strengthening Herborium's differential brand advantage. To that end, he will advise management regarding the Company's proactive clinical validation and regulatory strategy speared the U.S. Food and Drug Administration's (FDA) guidance for the botanical drug product industry (FDA Guidance 2004)."
"With Herborium's business model based on clinical testing confirmation of our products efficacy, having Dr. Mermelshein among our team of medical experts will also facilitate further advancement of our clinical testing, and therefore strengthen a differential advantage and marketability of our products growing," concluded Dr. Olszewski.
About Herborium Group, Inc.
Herborium Group, Inc., a botanical therapeutics® company, focuses on developing, licensing, and marketing proprietary, botanical based medicinal products to consumers and healthcare professionals. The Company business model focuses on emerging market opportunities spearheaded by the growth of a new market sector located between high-cost, high-risk, ethical pharmaceuticals and commoditized classic nutraceuticals (supplements). The Company uses clinical validation and a proactive regulatory strategy based on the FDA Guidance for Industry: Botanical Drug Products (FDA Guidance 2004) to establish and maintain a differential advantage. Herborium harvests its therapeutic candidates from Traditional Chinese Medicine and utilizes Western regulatory, clinical and marketing strategies to successfully introduce the products to the Western markets. The company secured a pipeline of botanical ingredients based products in the areas of dermatological needs, Prostate Health (BPH), Liver Diseases, Women's Health and selected sexual disorders resulting from cardiovascular disease, use of anti-depressants, surgical procedures, and other problems. Herborium Group sells its products in the United States, the United Kingdom, and continental Europe through a network of distributors, specialty retailers, and e-commerce.
One of our most important responsibilities is to communicate with shareholders in an open and direct manner. Comments are based on current management expectations, and are considered "forward-looking statements," generally preceded by words such as "plans," "expects," "believes," "anticipates," or "intends." We cannot promise future returns. Our statements reflect our best judgment at the time they are issued, and we disclaim any obligation to update or alter forward-looking statements as the result of new information or future events. Adino Energy Corporation urges investors to review the risks and uncertainties contained within its filings with the Securities and Exchange Commission.
<b>Company Contact:</b>Dr. Agnes P. OlszewskiPresident & CEO(201) 647-3757
Posts: 364 | Registered: Mar 2010
| IP: Logged |
posted
Having Dr. Mermelshein among our team of medical experts will also facilitate further advancement of our clinical testing, and therefore strengthen a differential advantage and marketability of our products growing," concluded Dr. Olszewski.
Posts: 364 | Registered: Mar 2010
| IP: Logged |
posted
HBRM - Holding on today and looking to do better and better. Could be the time to get in and hold on.
Posts: 143 | Registered: Apr 2010
| IP: Logged |
Herborium harvests its therapeutic candidates from Traditional Chinese Medicine and utilizes Western regulatory, clinical and marketing strategies to successfully introduce the products to the Western markets. The company secured a pipeline of botanical ingredients based products in the areas of dermatological needs, Prostate Health (BPH), Liver Diseases, Women's Health and selected sexual disorders resulting from cardiovascular disease, use of anti-depressants, surgical procedures, and other problems. Herborium Group sells its products in the United States, the United Kingdom, and continental Europe through a network of distributors, specialty retailers, and e-commerce.
Posts: 143 | Registered: Apr 2010
| IP: Logged |
UBBFriend: Email this page to someone!
Printer-friendly view of this topic
